The impact of the MYB-NFIB fusion proto-oncogene in vivo.

Oncotarget
Authors
Abstract

Recurrent fusion of the v-myb avian myelobastosis viral oncogene homolog (MYB) and nuclear factor I/B (NFIB) generates the MYB-NFIB transcription factor, which has been detected in a high percentage of individuals with adenoid cystic carcinoma (ACC). To understand the functional role of this fusion protein in carcinogenesis, we generated a conditional mutant transgenic mouse that expresses MYB-NFIB along with p53 mutation in tissues that give rise to ACC: mammary tissue, salivary glands, or systemically in the whole body. Expression of the oncogene in mammary tissue resulted in hyperplastic glands that developed into adenocarcinoma in 27.3% of animals. Systemic expression of the MYB-NFIB fusion caused more rapid development of this breast phenotype, but mice died due to abnormal proliferation in the glomerular compartment of the kidney, which led to development of glomerulonephritis. These findings suggest the MYB-NFIB fusion is oncogenic and treatments targeting this transcription factor may lead to therapeutic responses in ACC patients.

Year of Publication
2016
Journal
Oncotarget
Volume
7
Issue
22
Pages
31681-8
Date Published
2016 May 31
ISSN
1949-2553
URL
DOI
10.18632/oncotarget.9426
PubMed ID
27213588
PubMed Central ID
PMC5077968
Links
Grant list
R01 CA122794 / CA / NCI NIH HHS / United States
P01 CA120964 / CA / NCI NIH HHS / United States
R01 CA163896 / CA / NCI NIH HHS / United States
R01 CA166480 / CA / NCI NIH HHS / United States
R01 CA195740 / CA / NCI NIH HHS / United States
R01 CA140594 / CA / NCI NIH HHS / United States